Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole by Goss, P. E. et al.
13. Henry N, Jacobson J, Banerjee M et al. A prospective study of aromatase
inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-
resolution wrist ultrasonography. Cancer 2010; 116: 4360–4367.
14. Dizdar O, Ozçakar L, Malas F et al. Sonographic and electrodiagnostic
evaluations in patients with aromatase inhibitor-related arthralgia. J Clin Oncol
2009; 27: 4955–4960.
15. Au B. Clinical features of joint symptoms observed in the Arimidex,
Tamoxifen Alone or in Combination (ATAC) trial. Proc Am Soc Clin Oncol 2006;
24: 18S.
16. Kanematsu M, Morimoto M, Honda J et al. The time since last menstrual period
is important as a clinical predictor for non-steroidal aromatase inhibitor-related
arthralgia. BMC Cancer 2011; 11: 436.
17. Sestak I, Cuzick J, Sapunar F et al. Risk factors for joint symptoms in patients
enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol
2008; 9: 866–872.
18. World Medical Association. Review of the declaration of Helsinki. JAMA 1997;
227: 925–926.
19. Henry N, Giles J, Ang D et al. Prospective characterization of musculoskeletal
symptoms in early stage breast cancer patients treated with aromatase inhibitors.
Breast Cancer Res Treat 2008; 111: 365–372.
20. Cvoro A, Tatomer D, Tee M et al. Selective estrogen receptor-beta agonists
repress transcription of proinflammatory genes. J Immunol 2008; 180:
630–636.
21. Magliano M. Menopausal arthralgia: fact or fiction. Maturitas 2010; 67: 29–33.
22. Mao J, Stricker C, Bruner D et al. Patterns and risk factors associated with
aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer
2009; 115: 3631–3639.
23. Ingle JN, Schaid DJ, Goss PE et al. Genome-wide associations and functional
genomic studies of musculoskeletal adverse events in women receiving
aromatase inhibitors. J Clin Oncol 2010; 28: 4674–4682.
24. Ingle J, Buzdar A, Schaid D et al. Variation in anastrozole metabolism and
pharmacodynamics in women with early breast cancer. Cancer Res 2010; 70:
3278–3286.
25. Rae JM, Sestak I, Henry NL et al Correlation between gene variants in CYP19
(aromatase) and TCL1A with disease and tolerability endpoints in the ATAC trial.
In SABCS. San Antonio, 2011.
26. Park IH, Lee YS, Lee KS et al. Single nucleotide polymorphisms of CYP19A1
predict clinical outcomes and adverse events associated with letrozole in patients
with metastatic breast cancer. Cancer Chemother Pharmacol 2011; 68:
1263–1271.
Annals of Oncology 24: 355–361, 2013
doi:10.1093/annonc/mds330
Published online 1 October 2012
Impact of premenopausal status at breast cancer
diagnosis in women entered on the placebo-controlled
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Background: MA17 showed improved outcomes in postmenopausal women given extended letrozole (LET) after
completing 5 years of adjuvant tamoxifen.
Patients and methods: Exploratory subgroup analyses of disease-free survival (DFS), distant DFS (DDFS), overall
survival (OS), toxic effects and quality of life (QOL) in MA17 were performed based on menopausal status at breast
cancer diagnosis.
Results: At diagnosis, 877 women were premenopausal and 4289 were postmenopausal. Extended LET was
significantly better than placebo (PLAC) in DFS for premenopausal [hazard ratio (HR) = 0.26, 95% confidence interval
(CI) 0.13–0.55; P = 0.0003] and postmenopausal women (HR = 0.67; 95% CI 0.51–0.89; P = 0.006), with greater DFS
benefit in those premenopausal (interaction P = 0.03). In adjusted post-unblinding analysis, those who switched from
PLAC to LET improved DDFS in premenopausal (HR = 0.15; 95% CI 0.03–0.79; P = 0.02) and postmenopausal women
(HR = 0.45; 95% CI 0.22–0.94; P = 0.03).
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Conclusions: Extended LET after 5 years of tamoxifen was effective in pre- and postmenopausal women at
diagnosis, and significantly better in those premenopausal. Women premenopausal at diagnosis should be considered
for extended adjuvant therapy with LET if menopausal after completing tamoxifen.
Key words: adjuvant therapy, aromatase inhibitors, breast cancer, extended therapy, letrozole, menopausal status
introduction
Ovarian function suppression, tamoxifen, and aromatase
inhibitors (AI) antagonize estrogen in hormone-dependent
breast cancer [1]. Adjuvant therapy for women
postmenopausal at diagnosis with ER+ tumors includes 5 years
of tamoxifen or AI, or tamoxifen for 2–3 years followed by 2–3
years of AI, or 5 years of tamoxifen followed by 5 years of AI
[2]. In women premenopausal at diagnosis, standard adjuvant
therapy is 5 years of tamoxifen which decreases the risk of
recurrence and improves survival [3, 4]. Longer durations
afford no additional benefit [3, 5, 6].
MA17 is one of few adjuvant AI trials that included
women who were premenopausal at initial diagnosis [7].
The NCIC Clinical Trials Group (NCIC CTG) MA17 trial
randomized 5187 women who were within 3 months of
completing 4.5–6 years of tamoxifen and postmenopausal
after tamoxifen, to receive letrozole (LET) or placebo
(PLAC) [8]. At median follow-up of 2.5 years on extended
LET, disease-free survival (DFS) was improved [hazard
ratio (HR) 0.58, 95% confidence interval (CI) 0.45–0.76);
P < 0.001] as was survival in node-positive patients (N =
2594) in the initial analysis (HR 0.61, 95% CI 0.38–0.98;
P = 0.04), and a more recent analysis showed OS advantage
in the overall study population [9, 10]. Analysis after
unblinding and allowing late cross-over from PLAC to LET
improved DFS (adjusted HR 0.37; 95% CI 0.23–0.61;
P < 0.0001) and distant DFS (DDFS; HR 0.39; 95% CI
0.20–0.74; P = 0.004) at median follow-up of 5.3 years from
randomization on MA17 [11]. Despite 66% cross-over to
LET after unblinding, an intent-to-treat analysis of women
originally assigned to LET in MA17 showed improvement
in DFS (HR 0.68, 95% CI 0.55–0.83, P = 0.0001) in both
node-positive and -negative patients, as well in the risk of
contralateral breast cancer (CLBC; HR 0.61, 95% CI 0.39–
0.97, P = 0.033) [12].
All women on MA17 were postmenopausal at
randomization after completing tamoxifen, and although the
majority had also been postmenopausal at the time of
primary diagnosis, a minority had been premenopausal. In
light of known benefit of adjuvant ovarian function
suppression in premenopausal endocrine receptor-positive
disease [1, 13], we hypothesized differences in outcomes
between women on MA17 who were premenopausal at
original diagnosis and became postmenopausal by the time
they completed 5 years of tamoxifen, versus those who had
been postmenopausal from the beginning. Here, we report
analyses from the MA17 trial based on menopausal status at
the time of first diagnosis. In addition to our primary
analysis, we report outcomes among women who at
unblinding (at times 2–7 years after tamoxifen) were found
to be on placebo and were offered the choice of taking
letrozole or remaining on observation.
methods
study design
Details of the design and inclusion criteria for MA17 have been reported
previously [8, 9]. In brief, MA17 was a phase III, randomized, double-
blinded, PLAC-controlled trial investigating extended LET in women with
ER+ breast cancer who were postmenopausal after 5 years of initial
tamoxifen. Patients were randomized to LET 2.5 mg or PLAC daily for 5
years stratifying for hormone receptor status (positive or unknown), lymph
node involvement (positive, negative, or unknown), and prior
chemotherapy (yes or no). All patients were defined as postmenopausal
after tamoxifen and at the time of randomization by the following criteria:
≥50 years at the start of prior tamoxifen therapy; <50 years but
postmenopausal at the initiation of tamoxifen therapy; <50 years at the
start of tamoxifen but had undergone bilateral oophorectomy;
premenopausal and younger than 50 years at the start of tamoxifen therapy
but became amenorrhoeic during chemotherapy or treatment with
tamoxifen and had postmenopausal levels of luteinizing hormone (LH) or
follicle-stimulating hormone (FSH) (the minimum period of amenorrhea
was ≥1 year). After reaching the primary end point, MA17 was unblinded
in October 2003 after the first interim analysis demonstrated a statistically
highly significant improvement in DFS and an overall survival trend in
patients receiving LET compared with those receiving PLAC [8, 9]. At
unblinding, participants receiving PLAC were offered a choice of LET for a
planned period of 5 years.
All women randomized on MA17 continued follow-up annually until
death. Two databases were available for analyses: one comprising data
observed until unblinding October 2003 and one data up to July 2006. The
median follow-up for all patients in these two databases was 2.5 and 5.3
years with 4923 (95%) and 2383 (97%) women censored for DFS outcome,
respectively. For this analysis, all women randomized to MA17 were
divided into two groups: (i) premenopausal (<50 years of age with menses
but underwent bilateral oophorectomy at time when tamoxifen treatment
started, or <50 years of age with menses but became permanently
amenorrhoeic (≥12 months) from systemic chemotherapy, or on tamoxifen
and (ii) postmenopausal (≥50 years of age without menses at diagnosis or,
<50 years of age without menses and considered postmenopausal at
diagnosis, or considered postmenopausal by the virtue of menopausal LH/
FSH). Four patients missing menopausal status data were excluded. Details
of quality of life (QOL) measures were previously published [14].
statistical analysis
As in MA17, DFS was defined as the time from randomization to the time
of disease recurrence (in the breast, chest wall, nodal or metastatic sites), or
development of new CLBC. Deaths without recurrence, or without CLBC,
or secondary malignancy were not considered events. DDFS was defined as
time from randomization to time of distance recurrence. OS was defined
from randomization to death from any cause [8]. Because of potential
imbalances in baseline characteristics between women in the pre- and
postmenopausal groups, the chi-square test was used to perform univariate
analyses for the association between menopausal status and baseline
characteristics, and the logistic regression model was used to perform
multivariate analyses to identify independent baseline characteristics
associated with menopausal status. For time-to-event end points observed
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before unblinding, the hazard ratios and associated 95% CI’s and P values
between menopausal or treatment groups were obtained from a Cox
regression model adjusting for other potential prognostic factors including
LET or PLAC treatment, duration of prior tamoxifen, nodal status, and
prior chemotherapy. In the analyses of outcomes after unblinding, patients
who recurred or died before unblinding were excluded from the analyses.
In these analyses, hazard ratios of women randomized originally to PLAC
but who switched to LET after unblinding (PLAC–LET) were compared
with those for women who remained on observation (PLAC–PLAC), and
the associated 95% CI’s and P values were obtained from the Cox model,
adjusting for ethnicity (white versus nonwhite), age (<70 versus ≥70 years),
performance status (0 versus 1 or 2), time from initial diagnosis to random
assignment (<5 versus ≥5 years), pathologic N stage (0 versus other),
hormone receptor status (positive versus others), prior chemotherapy (yes
versus no), and axillary node dissection (yes versus no), all of which were
found to be significantly associated with the choice to switch to LET or
not. The Wilcoxon test was used to compare change scores of QOL
between the groups from baseline to 24 months after initial randomization.
results
patient population
Baseline patient and disease characteristics are shown in
Table 1. About 877 patients were identified as premenopausal
and 4289 as postmenopausal at diagnosis. A significantly
higher proportion of premenopausal than postmenopausal
women had ER+ PR+ versus ER+PR− tumors at diagnosis
(89.7% versus 84.9%; P = 0.0006). Univariate analyses showed
age, race, nodal status, prior adjuvant chemotherapy, and
mastectomy to be associated with menopausal status. By
multivariate analysis treatment, race, duration of tamoxifen,
prior adjuvant chemotherapy, and mastectomy were
independent factors associated with menopausal status.
patient outcomes after randomization
Table 2 shows DFS, DDFS, and OS, by menopausal status,
prior treatment at randomization, and nodal status based on
data before unblinding. For women randomized to LET,
postmenopausal women had the higher 4-year DFS rates
(90.5% versus 86.8%) and DDFS rates (93.9% versus 92.8%)
than premenopausal women but none was significant (DFS
HR 0.72, 95% CI 0.48–1.48; P = 0.11, and DDFS HR 0.98, 95%
CI 0.57–1.69; P = 0.95). As expected, 4-year OS was lower in
postmenopausal women but not statistically significantly so
(94.5% versus 96.8%; HR 2.33, 95% CI 0.80–6.76; P = 0.12).
LET was significantly better than PLAC in DFS for both
menopausal groups and in DDFS for postmenopausal women
with borderline significance for premenopausal women. No
difference in OS was found between the two treatments in
either of the menopausal groups. The interaction between
treatment and menopausal status was statistically significant for
DFS (P = 0.03) (Figure 1), which indicates that women
premenopausal at diagnosis experienced significantly greater
benefit (HR 0.26, 95% CI 0.13–0.55; P = 0.0003) with LET in
terms of DFS than those postmenopausal at diagnosis (HR
0.67, 95% CI 0.51–0.89; P = 0.006). The analyses by nodal
status showed a significant difference between LET and PLAC
in DFS for postmenopausal women with either node-negative
or -positive breast cancer and for premenopausal women with
positive nodes (premenopausal women with negative nodes
cannot be analyzed because no event was observed among
those who received LET); and in DDFS for postmenopausal
women with positive nodes.
patient outcomes after unblinding
The outcomes including data observed after unblinding for
women randomized to PLAC are presented in Table 3 by
menopausal status and whether women switched to LET. Both
pre- and postmenopausal women who switched to LET were
found to have higher 5-year DFS and DDFS rates than those
who remained on observation, which were statistically
significant except no significance in DFS was observed for
premenopausal women. Postmenopausal women who switched












Letrozole 418 (48) 2163 (50)
Placebo 459 (52) 2126 (50)
Age at randomization (years)
<60 877 (100) 1271 (30) <0.001 0.99
60–70 0 (0) 1694 (40)
≥70 0 (0) 1323 (31)
Missing 0 (0) 1 (0)
Race
White 779 (89) 3925 (92) 0.005 0.002
Black 33 (4) 146 (3)
Other 54 (6) 150 (4)
Unknown 5 (1) 39 (1)
Missing 6 (1) 29 (1)
Axillary lymph node status
Negative 369 (42) 2198 (51) <0.001 0.11
Positive 495 (56) 1863 (43)
Unknown 12 (1) 214 (5)
Missing 1 (0) 14 (0)
Hormone receptor status
Positive 860 (98) 4172 (97) 0.94 0.70
Negative 1 (0) 7 (0)
Unknown 10 (1) 81 (2)
Missing 6 (1) 29 (1)
Duration of prior tamoxifen
Treatment years
≤5 379 (43) 1988 (46) 0.09 0.01
>5 497 (57) 2294 (54)
Missing 1 (0) 7 (0)
Median (years) 5.01 5.01
Prior adjuvant chemotherapy
No 170 (19) 2650 (62) <0.001 <0.0001
Yes 705 (80) 1634 (38)





496 (57) 2436 (57) 0.90 0.37
Mastectomy 480 (55) 2119 (49) 0.004 0.07
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to LET also had a significantly longer OS than those remaining
on PLAC.
safety during blinded study
Table 4 presents subgroup analyses of toxic effects before
unblinding in each of the two menopausal groups.
Premenopausal women on LET had a lower incidence of
intermittent vaginal bleeding (10% versus 16%; P = 0.01) and
higher incidence of arthralgia (24% versus 16%; P = 0.004)
compared with those on PLAC. In contrast postmenopausal
women on LET had a higher incidence of hot flashes/flashes
(55% versus 50%; P = 0.001), arthralgia (25% versus 21%;
P = 0.002), myalgia (15% versus 12%; P = 0.007), and alopecia
(5% versus 3%; P = 0.003) than those on PLAC.
quality of life during blinded study
Supplementary Table S1, available at Annals of Oncology online
shows SF-36 and menopause-specific quality of life
(MENQOL) questionnaire measures by menopausal status and
treatment at 24 months. Higher scores in SF-36 domains
indicate better QOL whereas in MENQOL domains indicate
worse QOL. Change scores from baseline at 24 months from
randomization indicated that premenopausal women treated
with LET had significantly worse QOL than those treated with
PLAC in SF-36 role function-physical (−6.9 versus −1.5; P =
0.02), general health (−3.1 versus −0.05; P = 0.04), and vitality
(−7.0 versus 0.4; P = 0.001) domains and physical overall scale
(−1.8 versus 0.1; P = 0.04), while postmenopausal women
treated with LET had significantly worse QOL than those
treated by PLAC in MENQOL vasomotor (−0.2 versus −0.5;
P = 0.004) and sexual (0.2 versus −0.05; P = 0.01) domains at
24 months after randomization.
discussion
Five years of tamoxifen remains standard adjuvant endocrine
therapy for premenopausal women with low to moderate risk
early ER+ breast cancer [13].
Table 2. Outcomes before unblinding by menopausal status, treatment and nodal status for disease-free survival, distant disease-free survival and overall
survival
Group Letrozole Placebo Hazard ratioa (95% CI) Pa
N Four-year DFS (%) N Four-year DFS (%)
Disease-free survival
Premenopausal 418 96.5 459 86.8 0.26 (0.13–0.55) 0.0003
N+ 231 93.8 264 85.0 0.40 (0.18–0.85) 0.02
N− 182 100.0 187 88.5 NAb (NA–NA) NA
Postmenopausal 2163 93.9 2126 90.5 0.67 (0.51–0.89) 0.006
N+ 939 91.9 924 84.7 0.67 (0.47–0.95) 0.02
N− 1110 95.6 1088 94.5 0.58 (0.35–0.98) 0.04
Distant disease-free survival
Premenopausal 418 97.4 459 92.8 0.45 (0.20–1.02) 0.055
N+ 231 95.4 264 90.4 0.61 (0.26–1.46) 0.27
N− 182 100.0 187 95.6 NA (NA–NA) NA
Postmenopausal 2163 96.4 2126 93.9 0.64 (0.45–0.92) 0.02
N+ 939 94.8 924 88.2 0.51 (0.33–0.78) 0.002
N− 1110 97.9 1088 97.9 0.84 (0.40–1.76) 0.63
Overall survival
Premenopausal 418 99.3 459 96.8 0.43 (0.08–2.22) 0.31
N+ 231 98.8 264 94.4 0.51 (0.09–2.81) 0.44
N− 182 100.0 187 100.0 NA (NA–NA) NA
Postmenopausal 2163 94.6 2126 94.5 0.83 (0.57–1.22) 0.35
N+ 939 93.0 924 90.4 0.61 (0.38–1.00) 0.051
N− 1110 95.8 1088 97.7 1.49 (0.74–2.99) 0.26
aFrom multivariate Cox model for the comparison between letrozole and placebo.
bNo event was observed in one or both treatment arms.
Figure 1. Kaplan–Meier curves for DFS by treatment and menopausal
status
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Guidelines for premenopausal patients with higher risk of
recurrence differ, with ovarian function suppression often used
in combination with tamoxifen [15–17]. This difference is
reflected in the control arms of the ongoing ‘Suppression of
Ovarian Function Trial’ and the ‘Tamoxifen and Exemestane
Trial’, respectively [18, 19]. Longer than 5 years of tamoxifen
has not shown added benefit but increases toxicity [20], and
guidelines currently advise restricting use to 5 years.
The chances of permanent menopause from adjuvant
chemotherapy vary by age. Older premenopausal women and
those receiving more regimens that are dose-intensive regimens
or contain alkylating agents are more likely to become
menopausal [20]. Either way, women presenting
premenopausally with ER+ breast cancer frequently become
amenorrhoeic during the course of their adjuvant tamoxifen.
Deciding whether an amenorrhoeic woman is still
premenopausal by virtue of resumption of menses or
biochemical measurements can be inaccurate and make
decision whether AI monotherapy is appropriate and to avoid
unwanted pregnancy is difficult. In the MA17 clinical trial,
criteria of menopause after completion of tamoxifen and
before randomization to AI monotherapy were employed.
Table 3. Outcomes for patients randomized to placebo by menopausal status and nodal status according to whether they elected to receive letrozole after
unblinding
Group PLAC–LET PLAC–PLAC Hazard ratioa (95% CI) Pa
N Five-year outcome (%) N Five-year outcome (%)
Disease-free survival (DFS)
Premenopausal 287 98.8 134 90.5 0.39 (0.14–1.09) 0.07
Postmenopausal 1291 97.0 670 94.0 0.36 (0.21–0.62) 0.0003
Distant disease-free survival (DDFS)
Premenopausal 287 99.6 134 93.7 0.15 (0.03–0.79) 0.02
Postmenopausal 1291 98.1 670 96.7 0.45 (0.22–0.94) 0.033
Overall survival (OS)
Premenopausal 287 99.0 134 98.2 0.51 (0.06–4.11) 0.53
Postmenopausal 1291 98.1 670 93.0 0.28 (0.15–0.49) <0.0001
aFrom multivariate Cox model for the comparison between PLAC–LET and PLAC–PLAC.
Table 4. Patient self reported acute toxic effects (grade 1–4) by menopausal status and treatment
Toxicity Premenopausal Postmenopausal
Letrozole (N = 416) Placebo (N = 416) P Letrozole (N = 2161) Placebo (N = 2128) P
Edema 20 19 0.57 22 21 0.40
Hypertension 2 5 0.06 6 5 0.44
Hot flushes 69 68 0.84 55 50 0.001
Fatigue 37 33 0.16 39 40 0.60
Sweating 40 35 0.14 28 28 0.77
Anorexia 3 2 0.65 6 5 0.05
Constipation 12 12 0.88 14 15 0.42
Diarrhea 5 5 0.68 7 7 0.75
Nausea 10 12 0.28 12 12 0.82
Vaginal bleeding 10 16 0.01 5 6 0.16
Infection w/o neutropenia 4 5 0.20 5 4 0.13
Arthritis 4 2 0.29 7 6 0.14
High cholesterola 16 13 0.27 16 16 0.86
Dizziness 14 16 0.62 18 17 0.36
Insomnia 8 6 0.23 6 5 0.12
Depression 7 6 0.50 5 5 0.56
Headache 31 31 0.94 27 25 0.36
Arthralgia 24 16 0.004 25 21 0.002
Myalgia 16 12 0.16 15 12 0.007
Bone pain 6 5 0.95 5 6 0.60
Dyspnea 3 5 0.17 7 7 0.72
Alopecia 5 5 0.90 5 3 0.003
Vaginal dryness 11 8 0.29 5 4 0.40
aChange from normal to high.
From chi-square test for the comparison in the incidence of toxicity between letrozole and placebo.
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Fewer than 5 of 5187 women resumed regular menses on the
trial suggesting that the definition of menopause by these
criteria was very accurate and clinically useful. Our subgroup
analysis is interesting although only 877 of 5187 women
randomized to MA17 were premenopausal at initial diagnosis
of breast cancer. Not surprisingly premenopausal women in
our trial had higher breast cancer risk factors at baseline than
those postmenopausal as reflected by younger age, ethnicity,
and more frequent node-positive disease. Eighty percent of the
‘premenopausal’ cohort had received prior adjuvant
chemotherapy, likely contributing to their menopause.
The 4-year relapse rate in PLAC-treated women
premenopausal at diagnosis was 13.2% compared with 9.5% in
those postmenopausal. Among the premenopausal
improvement in DFS at 4 years was 9.7% and 3.4% in those
postmenopausal. The improvement in DFS was more
significant in premenopausal women than those
postmenopausal (P = 0.03 for interaction between treatment
and menopausal status). Premenopausal patients in general
presented more frequently with ER+ PR− rather than ER+ PR
+ primary tumors, with greater recurrence rates early in
follow-up. In contrast among our cohort of premenopausal
women ‘disease free at 5 years’, their primary tumors were
more commonly ER+ PR+ rather than ER+ PR− reinforcing
the notion that those with ER+PR− primary tumors have
disproportionately recurrence rates before completing 5 years
of tamoxifen. We previously published an analysis of all
women on MA17 showing that women with ER+ PR+ tumors
had superior outcomes on LET and the findings of a
significantly higher proportion of such tumors among our pre-
versus postmenopausal women is in keeping with these
previous findings [21]. Taken together, our results support the
notion that women with ER+ disease late in follow-up who
remain vulnerable to recurrence are more likely to have
micrometastatic disease that is estrogen sensitive and
responsive to reductions in circulating and tumor estrogen
levels with aromatase inhibition. We also previously published
results from MA17 showing that late administration of LET
confers a reduction in the risk of recurrence [10], and this was
also true in this analysis of women premenopausal at
diagnosis. This finding is clinically important in women who
have completed 5 years of tamoxifen some time before and did
not receive extended therapy and remain free of recurrence in
follow-up.
Finally, analysis of outcomes by nodal status in our patients
showed benefit from extended therapy with LET for both
subsets and in both pre- and postmenopausal women. A
remarkable finding in this analysis is that premenopausal
women with node-negative disease experienced 100% DFS on
extended LET. This is of great potential clinical significance
and merits follow-up.
Importantly, all MA17 participants regardless of age and
menopausal status had been able to tolerate 4.5–6 years of
prior tamoxifen, possibly making tolerability of further therapy
and compliance in this extended endocrine therapy setting
relatively better than among those receiving antiestrogen
therapy for the first time. Ultimately, the relative and absolute
benefits of taking extended LET immediately or delayed after
completing tamoxifen have to take into consideration several
factors, some of which are best ascertained by a ‘trial of
therapy’ as symptoms and QOL changes are not easy to predict
in any given patient. These include absolute and relative risks
of recurrent breast cancer or new CLBC, baseline symptoms of
menopause, and QOL. Regarding QOL in women who took
LET, our results showed that premenopausal women were
negatively affected in more domains than postmenopausal
women; however, this should be carefully interpreted since the
number of premenopausal women was smaller, and our
analysis was not corrected for multiple testing. Of importance
menopausal status should be carefully ascertained before
offering extended therapy with LET particularly as the
administration of AI as monotherapy to women can be both
ineffective and possibly induce unwanted pregnancies [22]. On
the basis of initial MA17 results, using the criteria employed in
MA17 is a reliable way to determine menopausal status after
tamoxifen, and combined with biochemical evaluation, should
enable confirmation of menopause. In the absence of a
prospective randomized clinical trial confined to women who
meet the criteria for ‘premenopausal’ status as defined here, the
findings from this analysis merit discussion with patients in
the clinic. This and other analyses we have published from
MA17 including the post-unblinding results, suggest that the
introduction of antiestrogen therapy at any time during follow-
up is likely to benefit patients in terms of breast cancer
outcomes, and this also merits discussion with patients.
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